Treatment Outcomes in Anaplastic Thyroid Cancer.

IF 1.7 Q4 ENDOCRINOLOGY & METABOLISM
Journal of Thyroid Research Pub Date : 2019-05-23 eCollection Date: 2019-01-01 DOI:10.1155/2019/8218949
Kelsey L Corrigan, Hannah Williamson, Danielle Elliott Range, Donna Niedzwiecki, David M Brizel, Yvonne M Mowery
{"title":"Treatment Outcomes in Anaplastic Thyroid Cancer.","authors":"Kelsey L Corrigan, Hannah Williamson, Danielle Elliott Range, Donna Niedzwiecki, David M Brizel, Yvonne M Mowery","doi":"10.1155/2019/8218949","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anaplastic thyroid cancer (ATC) is rare, accounting for 1-2% of thyroid malignancies. Median survival is only 3-10 months, and the optimal therapeutic approach has not been established. This study aimed to evaluate outcomes in ATC based on treatment modality.</p><p><strong>Methods: </strong>Retrospective review was performed for patients treated at a single institution between 1990 and 2015. Demographic and clinical covariates were extracted from the medical record. Overall survival (OS) was modeled using Kaplan Meier curves for different treatment modalities. Univariate and multivariate analyses were conducted to assess the relationships between treatment and disease characteristics and OS.</p><p><strong>Results: </strong>28 patients with ATC were identified (n = 16 female, n = 12 male; n = 22 Caucasian, n = 6 African-American; median age 70.9). Majority presented as Stage IVB (71.4%). Most patients received multimodality therapy. 19 patients underwent local surgical resection. 21 patients received locoregional external beam radiotherapy (EBRT) with a median cumulative dose of 3,000 cGy and median number of fractions of 16. 14 patients received systemic therapy (n = 11 concurrent with EBRT), most commonly doxorubicin (n = 9). 16 patients were never disease free, 11 patients had disease recurrence, and 1 patient had no evidence of disease progression. Median OS was 4 months with 1-year survival of 17.9%. Regression analysis showed that EBRT (HR: 0.174; 95% CI: 0.050-0.613; p=0.007) and surgical resection (HR: 0.198; 95% CI: 0.065-0.598; p=0.004) were associated with improved OS. Administration of chemotherapy was not associated with OS.</p><p><strong>Conclusions: </strong>Anaplastic thyroid cancer patients receiving EBRT to the thyroid area/neck and/or surgical resection had better OS than patients without these therapies, though selection bias likely contributed to improved outcomes since patients who can undergo these therapies tend to have better performance status. Prognosis remains poor overall, and new therapeutic approaches are needed to improve outcomes.</p>","PeriodicalId":17394,"journal":{"name":"Journal of Thyroid Research","volume":"2019 ","pages":"8218949"},"PeriodicalIF":1.7000,"publicationDate":"2019-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556325/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/8218949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Anaplastic thyroid cancer (ATC) is rare, accounting for 1-2% of thyroid malignancies. Median survival is only 3-10 months, and the optimal therapeutic approach has not been established. This study aimed to evaluate outcomes in ATC based on treatment modality.

Methods: Retrospective review was performed for patients treated at a single institution between 1990 and 2015. Demographic and clinical covariates were extracted from the medical record. Overall survival (OS) was modeled using Kaplan Meier curves for different treatment modalities. Univariate and multivariate analyses were conducted to assess the relationships between treatment and disease characteristics and OS.

Results: 28 patients with ATC were identified (n = 16 female, n = 12 male; n = 22 Caucasian, n = 6 African-American; median age 70.9). Majority presented as Stage IVB (71.4%). Most patients received multimodality therapy. 19 patients underwent local surgical resection. 21 patients received locoregional external beam radiotherapy (EBRT) with a median cumulative dose of 3,000 cGy and median number of fractions of 16. 14 patients received systemic therapy (n = 11 concurrent with EBRT), most commonly doxorubicin (n = 9). 16 patients were never disease free, 11 patients had disease recurrence, and 1 patient had no evidence of disease progression. Median OS was 4 months with 1-year survival of 17.9%. Regression analysis showed that EBRT (HR: 0.174; 95% CI: 0.050-0.613; p=0.007) and surgical resection (HR: 0.198; 95% CI: 0.065-0.598; p=0.004) were associated with improved OS. Administration of chemotherapy was not associated with OS.

Conclusions: Anaplastic thyroid cancer patients receiving EBRT to the thyroid area/neck and/or surgical resection had better OS than patients without these therapies, though selection bias likely contributed to improved outcomes since patients who can undergo these therapies tend to have better performance status. Prognosis remains poor overall, and new therapeutic approaches are needed to improve outcomes.

Abstract Image

Abstract Image

甲状腺无节细胞癌的治疗结果
背景:甲状腺无细胞癌(ATC)非常罕见,占甲状腺恶性肿瘤的1-2%。中位生存期仅为3-10个月,最佳治疗方法尚未确定。本研究旨在根据治疗方式评估ATC的治疗效果:方法:对1990年至2015年间在一家机构接受治疗的患者进行回顾性研究。从病历中提取了人口统计学和临床协变量。采用卡普兰-梅尔曲线对不同治疗方式的总生存期(OS)进行建模。进行了单变量和多变量分析,以评估治疗和疾病特征与OS之间的关系。结果:共发现28例ATC患者(女性16例,男性12例;白种人22例,非裔美国人6例;中位年龄70.9岁)。大多数患者为 IVB 期(71.4%)。大多数患者接受了多模式治疗。19名患者接受了局部手术切除。21 名患者接受了局部体外放射治疗(EBRT),中位累积剂量为 3,000 cGy,中位分次为 16 次。14名患者接受了全身治疗(11人与EBRT同时进行),其中最常见的是多柔比星(9人)。16名患者从未无病,11名患者疾病复发,1名患者无疾病进展迹象。中位生存期为4个月,1年生存率为17.9%。回归分析显示,EBRT(HR:0.174;95% CI:0.050-0.613;P=0.007)和手术切除(HR:0.198;95% CI:0.065-0.598;P=0.004)与OS的改善有关。化疗与OS无关:结论:接受甲状腺区域/颈部EBRT治疗和/或手术切除的甲状腺无节细胞癌患者的OS优于未接受这些治疗的患者,但选择偏倚可能是导致预后改善的原因之一,因为能接受这些治疗的患者往往有更好的表现状态。总体预后仍然不佳,需要新的治疗方法来改善预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Thyroid Research
Journal of Thyroid Research ENDOCRINOLOGY & METABOLISM-
CiteScore
4.40
自引率
0.00%
发文量
10
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信